Also, patients with ET/PV carrying both JAK2 and TET2 mutations at IFN start had less significant reduction in JAK2V617F allele burden compared with JAK2 mutant/TET2 wild-type patients [24]. Here, TET2 is linked to essential thrombocythemia.